Hunan Warrant Pharmaceutical Co. Ltd. A - Asset Resilience Ratio
Hunan Warrant Pharmaceutical Co. Ltd. A (688799) has an Asset Resilience Ratio of 0.40% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Hunan Warrant Pharmaceutical Co. Ltd. A (688799) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2024)
This chart shows how Hunan Warrant Pharmaceutical Co. Ltd. A's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 688799 total asset value.
Liquid Assets Composition Over Time
This chart breaks down Hunan Warrant Pharmaceutical Co. Ltd. A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read 688799 total debt and obligations for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥10.00 Million | 0.4% |
| Total Liquid Assets | CN¥10.00 Million | 0.40% |
Asset Resilience Insights
- Limited Liquidity: Hunan Warrant Pharmaceutical Co. Ltd. A maintains only 0.40% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Hunan Warrant Pharmaceutical Co. Ltd. A Industry Peers by Asset Resilience Ratio
Compare Hunan Warrant Pharmaceutical Co. Ltd. A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423 |
Drug Manufacturers - Specialty & Generic | 20.44% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Piramal Pharma Limited
NSE:PPLPHARMA |
Drug Manufacturers - Specialty & Generic | 0.73% |
|
Harbin Gloria Pharmaceuticals
SHE:002437 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
Annual Asset Resilience Ratio for Hunan Warrant Pharmaceutical Co. Ltd. A (2021–2024)
The table below shows the annual Asset Resilience Ratio data for Hunan Warrant Pharmaceutical Co. Ltd. A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 7.44% | CN¥183.00 Million ≈ $26.78 Million |
CN¥2.46 Billion ≈ $359.92 Million |
+6.75pp |
| 2023-12-31 | 0.69% | CN¥15.00 Million ≈ $2.19 Million |
CN¥2.18 Billion ≈ $318.56 Million |
-15.49pp |
| 2022-12-31 | 16.18% | CN¥325.00 Million ≈ $47.56 Million |
CN¥2.01 Billion ≈ $293.98 Million |
-6.08pp |
| 2021-12-31 | 22.25% | CN¥400.00 Million ≈ $58.53 Million |
CN¥1.80 Billion ≈ $263.04 Million |
-- |
About Hunan Warrant Pharmaceutical Co. Ltd. A
Hunan Warrant Pharmaceutical Co.,Ltd manufactures and sells pharmaceutical products. It offers medicines in the areas of digestive, berating, anti-infection, gynecology, cardiovascular, cerebrovascular, immunology and nephrology, and other fields. Hunan Warrant Pharmaceutical Co.,Ltd was founded in 2001 and is based in Changsha, China.